365 related articles for article (PubMed ID: 18844597)
1. Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus.
Olson MR; Varga SM
Expert Rev Vaccines; 2008 Oct; 7(8):1239-55. PubMed ID: 18844597
[TBL] [Abstract][Full Text] [Related]
2. Mucosal vaccines against respiratory syncytial virus.
Yang K; Varga SM
Curr Opin Virol; 2014 Jun; 6():78-84. PubMed ID: 24794644
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-27 inhibits vaccine-enhanced pulmonary disease following respiratory syncytial virus infection by regulating cellular memory responses.
Zeng R; Zhang H; Hai Y; Cui Y; Wei L; Li N; Liu J; Li C; Liu Y
J Virol; 2012 Apr; 86(8):4505-17. PubMed ID: 22301139
[TBL] [Abstract][Full Text] [Related]
4. Intranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model.
Passmore C; Makidon PE; O'Konek JJ; Zahn JA; Pannu J; Hamouda T; Bitko V; Myc A; Lukacs NW; Fattom A; Baker JR
Hum Vaccin Immunother; 2014; 10(3):615-22. PubMed ID: 24326268
[TBL] [Abstract][Full Text] [Related]
5. A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease.
Lindell DM; Morris SB; White MP; Kallal LE; Lundy PK; Hamouda T; Baker JR; Lukacs NW
PLoS One; 2011; 6(7):e21823. PubMed ID: 21789184
[TBL] [Abstract][Full Text] [Related]
6. Unveiling Integrated Functional Pathways Leading to Enhanced Respiratory Disease Associated With Inactivated Respiratory Syncytial Viral Vaccine.
Russell MS; Creskey M; Muralidharan A; Li C; Gao J; Chen W; Larocque L; Lavoie JR; Farnsworth A; Rosu-Myles M; Hashem AM; Yauk CL; Cao J; Van Domselaar G; Cyr T; Li X
Front Immunol; 2019; 10():597. PubMed ID: 30984178
[TBL] [Abstract][Full Text] [Related]
7. Impairment of T cell immunity by the respiratory syncytial virus: targeting virulence mechanisms for therapy and prophylaxis.
González PA; Bueno SM; Riedel CA; Kalergis AM
Curr Med Chem; 2009; 16(34):4609-25. PubMed ID: 19903147
[TBL] [Abstract][Full Text] [Related]
8. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.
Lambert SL; Aslam S; Stillman E; MacPhail M; Nelson C; Ro B; Sweetwood R; Lei YM; Woo JC; Tang RS
PLoS One; 2015; 10(3):e0119509. PubMed ID: 25793508
[TBL] [Abstract][Full Text] [Related]
9. Induction and Subversion of Human Protective Immunity: Contrasting Influenza and Respiratory Syncytial Virus.
Ascough S; Paterson S; Chiu C
Front Immunol; 2018; 9():323. PubMed ID: 29552008
[TBL] [Abstract][Full Text] [Related]
10. New insights for development of a safe and protective RSV vaccine.
Blanco JC; Boukhvalova MS; Shirey KA; Prince GA; Vogel SN
Hum Vaccin; 2010 Jun; 6(6):482-92. PubMed ID: 20671419
[TBL] [Abstract][Full Text] [Related]
11. Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice.
Cayatte C; Snell Bennett A; Rajani GM; Hostetler L; Maynard SK; Lazzaro M; McTamney P; Ren K; O'Day T; McCarthy MP; Schneider-Ohrum K
PLoS One; 2017; 12(11):e0188708. PubMed ID: 29182682
[TBL] [Abstract][Full Text] [Related]
12. In Hot Pursuit of the First Vaccine Against Respiratory Syncytial Virus.
Kim JY; Chang J
Yonsei Med J; 2016 Jul; 57(4):809-16. PubMed ID: 27189271
[TBL] [Abstract][Full Text] [Related]
13. Determinants of early life immune responses to RSV infection.
Ruckwardt TJ; Morabito KM; Graham BS
Curr Opin Virol; 2016 Feb; 16():151-157. PubMed ID: 26986236
[TBL] [Abstract][Full Text] [Related]
14. Passive and active immunization against respiratory syncytial virus for the young and old.
Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
[TBL] [Abstract][Full Text] [Related]
16. Protection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin.
Lee YN; Hwang HS; Kim MC; Lee YT; Kim YJ; Lee FE; Kang SM
Nanomedicine; 2016 Apr; 12(3):759-770. PubMed ID: 26656630
[TBL] [Abstract][Full Text] [Related]
17. A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats.
Kamphuis T; Stegmann T; Meijerhof T; Wilschut J; de Haan A
Influenza Other Respir Viruses; 2013 Nov; 7(6):1227-36. PubMed ID: 23575113
[TBL] [Abstract][Full Text] [Related]
18. Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis.
Jorquera PA; Anderson L; Tripp RA
Expert Rev Vaccines; 2016; 15(2):173-87. PubMed ID: 26641318
[TBL] [Abstract][Full Text] [Related]
19. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
[TBL] [Abstract][Full Text] [Related]
20. RSV 2007: recent advances in respiratory syncytial virus research.
Stevens WW; Falsey AR; Braciale TJ
Viral Immunol; 2008 Jun; 21(2):133-40. PubMed ID: 18570587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
